

α 4 Integrin Increases Anoikis of Human Osteosarcoma Cells

Rex A. W. Marco,¹ C. Marcela Díaz-Montero,² James N. Wygant,² Eugenie S. Kleinerman,³ and Bradley W. McIntyre^{2*}

¹Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

²Department of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

³Department of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abstract Cell motility, growth, and proliferation are regulated by adhesion to the extracellular matrix. Detachment of adherent cells from extracellular matrix results in induction of apoptosis ("anoikis"). Transformed cells often show an anchorage-independent growth that enables them to acquire a motile, invasive phenotype. This phenotype has been associated with the altered expression and function of the integrin family of transmembrane proteins that mediate cell adhesion to the extracellular matrix. Although α 4 integrin is normally expressed on leukocyte subpopulations, a number of metastatic melanomas and sarcomas express it as well. In this study, we demonstrated the expression of α 4 integrins on the human osteosarcoma cell line SAOS and on metastatic osteosarcoma lesions from the lung and pericardium. We further demonstrated that α 4 integrin is coupled to the β 1 subunit by biochemical analysis and by using a mAb directed against a combinatorial epitope unique to the α 4 β 1 molecule. SAOS cells undergo anoikis when adherence is denied. Anoikis involved the activation of caspase 3 and the release of cytochrome c from mitochondria. Treatment of non-adherent SAOS with an anti- α 4 mAb increased anoikis while anti- β 1 integrin mAbs did not alter anoikis, thus indicating a novel function for the α 4 subunit in the control of cell death. Since integrins can control cell migration, proliferation, and apoptosis these results demonstrate a potential role for α 4 integrin during multiple aspects of osteosarcoma metastasis. *J. Cell. Biochem.* 88: 1038–1047, 2003. © 2003 Wiley-Liss, Inc.

Key words: apoptosis; extracellular matrix; osteogenic sarcoma; cell adhesion; metastasis

Cell adhesion has a complex relationship with cancer and, ultimately, the diagnosis and management of this disease will require an understanding of this association. After normal cells become transformed many events connected with adhesion can occur such as loss of contact

inhibition of growth, detachment from other cells and extracellular matrix, invasion of surrounding tissue, extravasation, and metastasis to distinct anatomical sites. Adhesion not only regulates the location and motility of tumor cells, but growth and proliferation can also be controlled by adhesive mechanisms. An obvious mechanism for growth regulation would be the tissue specific homing of metastatic cells to a region containing appropriate growth factors. Undeniably this can occur, but it has recently become clear that cell adhesion receptors can transmit intracellular signals that can positively or negatively regulate cell growth and arrest [Schwartz and Assoian, 2001]. Another mechanism for adhesion control of growth and metastasis is anoikis. Anoikis is defined as cell death induced by the lack of adhesion. It was first described in endothelial and epithelial cells where it maintains a dynamic balance of cell turnover [Meredith et al., 1993; Frisch and

Grant sponsor: NIH; Grant numbers: CA 42992 (to E.S.K.), CA 62596 (to B.M.W.), CA 16672; Cancer Center Support Core Grant (to the University of Texas M. D. Anderson Cancer Center); Grant sponsor: The Onstead Foundation.

*Correspondence to: Bradley W. McIntyre, Department of Immunology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 180, Houston, TX 77030.

E-mail: bmcintyr@mail.mdanderson.org.

Received 17 September 2002; Accepted 20 November 2002

DOI 10.1002/jcb.10465

© 2003 Wiley-Liss, Inc.

Francis, 1994]. Resistance to anoikis has been associated with malignancy, since it affords the cells increased survival time in the absence of matrix, facilitating their migration and eventual colonization of secondary sites [Yawata et al., 1998; Streuli and Gilmore, 1999; Shanmugathan and Jothy, 2000]. Thus the identification and characterization of tumor cell adhesion receptors that control cell cycle arrest, apoptosis, or proliferation may lead to the development of anti-cancer strategies.

Integrins are a family of heterodimeric transmembrane receptors that bind to various extracellular and cell surface proteins during adhesion, migration, and homing of normal and neoplastic cells [Meredith et al., 1996]. Furthermore, integrins may play a role in the ability of tumor cells that have become non-adherent to survive and metastasize [Frisch and Screaton, 2001]. Due to this central role in normal and pathologic cellular physiology, the determination of integrin expression patterns in normal and diseased cells should be useful as diagnostic and prognostic markers and provide attractive targets for developing therapeutic drugs.

Osteosarcoma is the most common malignant primary bone tumor. Up to 80% of patients show macroscopic and microscopic pulmonary metastases at presentation. Effective adjuvant chemotherapy has improved long-term disease free 5-year survival rates from 10 to 20% in 1970s to nearly 60–70% [Link et al., 1986; Sluga et al., 1999]. Treatment of patients with relapsed disease requires intensive chemotherapy with limited efficacy [Goorin et al., 1991; Ferguson and Goorin, 2001]. New therapeutic approaches are therefore needed to improve patient survival. Studying the cellular mechanisms involved in the metastatic process may provide alternative treatments that may prevent or reduce tumor cell migration.

An experimental *in vitro* model using the human osteosarcoma cell line, SAOS-2 (SAOS) was used in our studies. SAOS cells were derived from a primary osteosarcoma lesion from an 11 year-old girl [Fogh et al., 1977]. SAOS cells are unable to form metastases in nude mice, however, multiple *in vivo* passages result in variants with high metastatic potential [Jia et al., 1999].

Expression of α 4 integrins in the human adult is normally restricted to monocytes, and B and T lymphocytes but during the tumorigenic pro-

cess a number of cell types such as metastatic melanomas and sarcomas express the α 4 integrin [Schweighoffer et al., 1993; Erle et al., 1994; Holzmann et al., 1998]. In this study, we showed the expression of α 4 and β 1 integrin subunits in human osteosarcoma metastatic lesions and in SAOS cells. Furthermore, because modulation of integrin function has different effects on cell fate, the role of α 4 integrin during anoikis of SAOS cells was also investigated. We found that the addition of soluble mAbs against the α 4 integrin enhanced anoikis in suspended SAOS cultures, thus suggesting a unique role for α 4 integrins in controlling cell death.

MATERIALS AND METHODS

Cell Culture and Tissue

The human osteosarcoma cell line SAOS-2 (SAOS) was obtained from the American Type Culture Collection (Manassas, VA). SAOS cells were maintained in Eagle's MEM (BioWhittaker, Walkersville, MD), 2 mM L-glutamine, 1 mM sodium pyruvate and non-essential amino acids (Sigma, St. Louis, MO). SAOS cells were cultured for 24 h at 37°C with or without soluble mAbs (10 μ g/ml) on untreated tissue culture plastic or on tissue culture plastic coated with poly (2-hydroxyethyl methacrylate) (poly-HEMA) (Sigma) at a density of 5 mg/cm². Poly-HEMA was prepared by dissolving it in 95% ethanol to a concentration of 50 mg/ml. After poly-HEMA was added, wells were allowed to dry overnight under sterile conditions in a laminar flow hood. Tissue samples were obtained from a 22-year-old patient diagnosed with fibroblastic osteosarcoma of the right distal femur. Tissue samples from metastatic lesions of the lung (0.831 g) and the pericardium (1.13 g) were obtained after left thoracotomy performed 2 years after diagnosis.

Monoclonal Antibodies

Monoclonal antibodies used in these studies were: anti- α 1 mAb TS2/7 [Hemler et al., 1984], anti- α 2 mAb P1E6, anti- α 3 mAb P1B5 [Wayner et al., 1988], anti- α 4 mAbs 90B8, L25, B5G10 [Hemler et al., 1984, 1987; McIntyre et al., 1989], anti- α 5 mAb P1D6 [Wayner et al., 1988], anti- α 6 G0H3 [Sonnenberg et al., 1987], anti- β 1 mAbs 18D3, 33B6, and 87B9 [Bednarczyk et al., 1992, 1993], anti- β 4 mAb 439-9B [Falcioni et al., 1988], anti- α 4 β 1 mAb

19H8 [Bednarczyk et al., 1994], anti- $\alpha 4\beta 7$ mAb ACT-1 [Schweighoffer et al., 1993], anti-CD26 mAb AC7 [Bednarczyk et al., 1991], anti-human MHC Class I mAb W6/32 [Barnstable et al., 1978] and anti-T cell receptor mAb T40/25 [Kappler et al., 1983]. All mAb were mouse anti-human except the rat anti-human GoH3.

Iodination of Purified mAb

Purified mAb were radioiodinated using 1,3,4,6-tetrachloro-3 α ,6 α , diphenylglycoluril (IODO-GEN, Pierce Chemical Co). Briefly, 25 μ g of purified mAb in 100 μ l of phosphate buffered saline (PBS) was added to an IODO-GEN coated 12 \times 75 mm glass tube (10 μ g of IODO-GEN/tube). The iodination reaction was initiated by the addition of 500 μ Ci of Na¹²⁵I (Du Pont-New England Nuclear) and allowed to continue for 15 min at room temperature. The reaction was stopped by removal of the mAb sample from the tube. ¹²⁵I-mAb was separated from free iodine by gel filtration on Sephadex G-25 fine matrix (Pharmacia LKB Biotechnology Inc., Uppsala, Sweden) equilibrated in PBS with 0.5% bovine serum albumin (Intergen Purchase, NY) and 0.02% sodium azide.

Iodination of Cell Surface Proteins and Immunoprecipitation

Cell surface proteins were labeled by lactoperoxidase-catalyzed radioiodination by a modification of a procedure described previously [Keski-Oja et al., 1977]. Briefly, 2–3 \times 10⁶ cells were washed three times in PBS and once in PBS with 1 μ M potassium iodide (KI). Cells were resuspended in 500 μ l of PBS with 1 μ M KI and 10 μ g of lactoperoxidase (Sigma) and 0.2 IU of glucose oxidase (Sigma) were added. Next, 1.0 mCi of Na¹²⁵I in 500 μ l of PBS with 1 μ M KI and 10 mM glucose was added and the sample was incubated at room temperature. After 15 min the cells were washed three times in ice-cold PBS containing 5 mM KI. ¹²⁵I-labeled cells were lysed in lysis buffer (150 mM NaCl, 10 mM Tris-HCl, pH 8.0 containing protease inhibitors: leupeptin at 10 μ g/ml, pepstatin A at 1 μ g/ml, aprotinin at 10 μ g/ml, and sodium azide 0.02% v/v (Sigma) with 2% CHAPS (Sigma)) for 1 h on ice. Clarified lysate was precleared with fixed *S. aureus* (Sigma) and then immunoprecipitated with protein A agarose beads (Roche, Indianapolis, IN) precomplexed with goat anti-mouse immunoglobulins (ICN, Costa Mesa, CA)

and relevant mAb, by incubation at 4°C for 16 h. Polypeptides were eluted by boiling in reducing Laemmli sample buffer, and separated by 7.5% SDS-PAGE. Dried gels were exposed to Kodak XR film at –80°C.

Binding Assay

Purified mAb (20 μ g/ml PBS) was added to the wells of a polyvinyl chloride microtiter plate (50 μ l/well) and incubated for 12 h at 4°C. Excess antibody was aspirated, and the plates were washed three times with PBS. Each well was treated with 250 μ l of 0.5% BSA/PBS for 4 h at room temperature, and the unbound BSA was removed. Tissue samples from a left upper lobe lung osteosarcoma (0.831 g) and from the pericardium (1.13 g) were lysed in 1% Triton, 150 mM NaCl, 10 mM Tris-HCl, 0.02% v/v sodium azide pH 7.5 with or without 1 mM MnCl₂, 1 mM MgCl₂, 1 mM CaCl₂ for 1 h on ice. BSA/PBS was added to lysates to a final concentration of 5 mg/ml, and 50 μ l of this mixture was added to each well. After incubation for 5 h at 4°C, the wells were washed four times with the appropriate lysis buffer diluted with an equal volume of 0.1% BSA/PBS (wash buffer). Radioiodinated antibody (1 \times 10⁶ cpm/50 μ l of wash buffer) was added to each well and incubated for 1 h at 4°C. The plates were washed five times with a buffer to remove unbound radioactivity, and the wells were counted for bound radioactivity in a LKB 1272 CliniGamma gamma counter (Pharmacia, Turku, Finland). Each data point represents the average from triplicate samples.

Cell Surface Staining and Flow Cytometry

Cells were washed twice with fluorescence activated cell sorter (FACS) buffer (PBS containing 0.1% FCS, 0.02% sodium azide), and incubated for 1 h at 37°C with 1 μ g/ml purified mAb. Following two washes in FACS buffer, cells were incubated with 1:100 dilution of FITC-conjugated goat anti-mouse IgG (ICN) or PE-conjugated goat anti-rat IgG (Caltag Laboratories, Burlingame, CA) for 1 h at 4°C. Following two washes with FACS buffer, fluorescence was analyzed on an Epics Profile flow cytometer (Coulter, Miami, FL).

Cell Cycle Analysis

Cell cycle analyses were performed using propidium iodide (PI) staining with subsequent

FACS analysis. Cells/well (5×10^5) were cultured either on plastic or poly-HEMA treated 6 well tissue culture plates for 24 h at 37°C in a 5% CO₂ atmosphere. After incubation, adherent cells were detached with trypsin (0.5% trypsin/0.1% EDTA in PBS). Cells were harvested in complete EMEM medium and centrifuged at 500g for 10 min. Pellets were washed with PBS and fixed with cold 75% ethanol overnight at 4°C. After fixation, cells were washed with PBS and stained with 500 μ l of PI solution (50 μ g/ml in PBS). Cells were incubated at 37°C for 30 min and analyzed by flow cytometry on an Epics Profile flow cytometer (Coulter).

Cytochrome c Release Measurements

Cytochrome c release from mitochondria was determined by Western immunoblot. Treated and untreated SAOS cells were harvested and centrifuged at 500g for 5 min. Pellets were gently lysed for 5 min in ice-cold lysis buffer (25 mM Tris and 5 mM MgCl₂, pH 7.4). Lysates were centrifuged for 5 min at 16,000g. Supernatants from equal number of cells (1×10^6) were mixed with $1 \times$ Laemmli reducing buffer and resolved by 15% SDS-PAGE. Polypeptides were transferred to nitrocellulose membranes (0.2 μ M, Schleicher & Schuell, Keene, NH). Cytochrome c was detected by immunoblotting with the monoclonal antibody clone 7H8.2C12 (Pharmingen, San Diego, CA).

Capase-3 Activity Assay

Treated and untreated SAOS cells (1×10^6) were lysed in 100 μ l lysis buffer (100 mM HEPES, 10% sucrose, 0.1% CHAPS, 1 mM EDTA, 10 mM DTT, 2 mM PMSF, 100 μ M pepstatin, 10 μ g/ml leupeptin, pH 7.5). Lysates were incubated at 4°C overnight. After incubation, 900 μ l of reaction buffer (100 mM HEPES, 10% sucrose, 0.1% CHAPS, 1 mM EDTA) was added to each sample. Two microliters of 25 mM solution (in DMSO) of fluorogenic substrate specific for caspase 3 (Ac-Asp-Glu-Val-Asp-AMC ammonium salt) were added. Samples were incubated at 37°C for 1 h and analyzed at excitation 380 nm and emission 480 nm (RF-1501 spectrofluorimeter Shimadzu Scientific Instruments, Columbia, MD). Relative fluorescence was calculated by subtracting the blank fluorescence (buffer plus substrate) from the experimental fluorescence.

RESULTS

Human Osteosarcoma Metastatic Lesions of the Lung and Pericardium Express $\alpha 4$ Integrin Subunit in Association With the $\beta 1$ Subunit

A solid phase double determinant binding assay was used to detect the expression of $\alpha 4$ integrin in Triton X-100 lysates of osteosarcoma metastatic lesions of the lung and pericardium. Radioiodinated anti- $\alpha 4$ mAb L25 was used to detect antigens bound by capture antibodies immobilized in plastic wells. No mAb L25 was captured by antigens presented by BSA, the control anti-T cell receptor mAb T40/25, or anti-CD26 mAb AC7 (Fig. 1). In contrast, the mAb B5G10, which binds to an $\alpha 4$ epitope that is spatially distinct from the mAb L25 binding site, clearly binds and presents the integrin $\alpha 4$ to mAb L25.

The results in Figure 1 demonstrate that human osteosarcoma cells express the integrin $\alpha 4$ subunit. In order to confirm that this alpha subunit is associated with the $\beta 1$ subunit, cells were lysed with Triton X-100 containing divalent cations to preserve integrin subunit integrity, and binding assays performed with radioiodinated anti- $\alpha 4$ mAb L25. Again, no mAb L25 was captured by antigens presented by BSA, the control anti-T cell receptor mAb T40/25, or anti-CD26 mAb AC7 (Fig. 2). When the




Fig. 1. Expression of integrin $\alpha 4$ on human osteosarcoma. mAb or BSA adsorbed to wells of a microtiter plate were used to capture antigens from 1% Triton lysates of metastatic lesions of pericardium and lung. Radioiodinated anti- $\alpha 4$ mAb L25 was used to detect bound antigens as described under Materials and Methods. The capture antibodies used were the anti-T cell receptor mAb T40/25, the anti- $\alpha 4$ subunit specific mAb B5G10, and the anti-CD26 mAb AC7. Data are expressed as the average \pm SEM from triplicate determinations. Where error bars are not indicated, SEM was smaller than the data point symbol.




Fig. 2. Integrin $\alpha 4$ subunit is associated with the integrin $\beta 1$ subunit on human osteosarcoma. mAb or BSA adsorbed to wells of a microtiter plate were used to capture antigens from 1% Triton (plus divalent cations) lysates of metastatic lesions of pericardium and lung. Radiiodinated anti- $\alpha 4$ mAb L25 was used to detect bound antigens as described under Materials and Methods. The capture antibodies used were the anti-T cell receptor mAb T40/25, the anti- $\beta 1$ subunit specific mAb 18D3, and the anti-CD26 mAb AC7. Data are expressed as the average \pm SEM from triplicate determinations. Where error bars are not indicated, SEM was smaller than the data point symbol.

anti- $\beta 1$ integrin subunit mAb 18D3 was used to capture antigens, radiolabeled L25 could now be detected. These results show that metastatic human osteosarcoma cells express the integrin $\alpha 4$ in association with the $\beta 1$ subunit. Expression of the $\alpha 4\beta 1$ integrins was also found in primary osteosarcoma tumors by flow cytometry (data not shown).

Expression of the Integrin $\alpha 4\beta 1$ by the SAOS Human Osteosarcoma Cell Line

Human SAOS osteosarcoma cells were examined for cell surface expression of the integrin $\alpha 4\beta 1$ by immunoprecipitation from detergent lysates of radioiodinated cells (Fig. 3). When immunoprecipitated with an anti- $\alpha 4$ mAb, the control $\alpha 4\beta 1^+$ HPB-ALL human T leukemic cells showed the $\alpha 4$ subunit at 150 kDa, the $\alpha 4$ fragments of 85 and 70 kDa, and the $\beta 1$ subunit at 130 kDa (lane 1). An identical pattern was obtained with the anti- $\beta 1$ mAb (lane 2) indicating that the integrin $\alpha 4\beta 1$ is the major $\beta 1$ integrin family member on these cells. With SAOS cells, $\alpha 4$ in association with $\beta 1$ was clearly seen (lane 5). The $\beta 1$ specific mAb precipitates $\alpha 4\beta 1$ and another higher molecular weight alpha subunit of approximately 200 kDa, probably the integrin $\alpha 1$ subunit (lane 6). The integrin $\alpha 2$ specific mAb did not immunoprecipitate a signi-




Fig. 3. Immunoprecipitation of $\alpha 4$ and $\beta 1$ integrins from the human osteosarcoma cell line SAOS. Radioiodinated HPB-ALL (lanes 1–4) and SAOS (lanes 5–8) cells were solubilized with detergent and polypeptides were immunoprecipitated with anti- $\alpha 4$ mAb L25 (lanes 1 and 5), anti- $\beta 1$ mAb 18D3 (lanes 2 and 6), anti-T cell receptor mAb T40/25 (lanes 3 and 7), and anti- $\alpha 2$ mAb P1E6 (lanes 4 and 8).

ficant amount of radiolabeled proteins from both HPB-ALL and SAOS cells (lanes 4 and 8).

SAOS cells were examined for the expression of a variety of integrin subunits by flow cytometry to confirm the results of Figure 3. As shown in Table I, the integrin subunits $\alpha 1$, $\alpha 4$, and $\beta 1$ appear to be highly expressed integrins on these cells when considering both percent

TABLE I. FACS Analysis of SAOS Integrins

| | % + | M.F.I. |
|-------------------|------|--------|
| FITC control | 2.1 | 0.49 |
| PE control | 1.9 | 0.63 |
| $\alpha 1$ | 51.4 | 3.85 |
| $\alpha 2$ | 5.1 | 0.88 |
| $\alpha 3$ | 23.2 | 1.86 |
| $\alpha 4$ | 72.8 | 6.24 |
| $\alpha 5$ | 18.7 | 1.73 |
| $\alpha 6$ | 16.4 | 1.48 |
| $\beta 1$ | 74.9 | 11.20 |
| $\beta 4$ | 3.3 | 0.61 |
| $\alpha 4\beta 1$ | 63.0 | 5.22 |
| $\alpha 4\beta 7$ | 2.5 | 0.52 |

positive and mean fluorescence intensity (MFI). These results also indicate that SAOS cell express the integrin $\alpha 4\beta 1$ instead of $\alpha 4\beta 7$. Altogether the results from the Figure 3 and Table I indicate that the two major $\beta 1$ integrins on SAOS cells are $\alpha 1\beta 1$ and $\alpha 4\beta 1$.

SAOS Undergo Apoptosis When Adherence is Denied

A significant fraction of SAOS cells underwent apoptosis (anoikis) after adherence was denied by culture in poly-HEMA treated plates (Fig. 4). Apoptosis was determined by PI staining followed by flow cytometry analysis. Figure 4 shows 51.8% of SAOS cells in the sub-G₀/G₁ apoptotic phase after culture in non-adherent conditions, compared to 10.3% in the adherent conditions.

Anoikis of SAOS Involves the Release of Cytochrome c From Mitochondria and Activation of the Caspase Cascade

To further investigate the mechanism by which anoikis occurs, the involvement of cytochrome c release from mitochondria and the subsequent activation of the caspase cascade was studied. Increased levels of cytochrome c, as shown in Figure 5 (panel A), were detected by Western immunoblot in the cytoplasm of SAOS cells after culture in suspension. Caspase 3 activity was determined using a specific fluorogenic substrate, which upon protease cleavage releases a fluorogenic product that can be quantitated by a spectrofluorimeter. Caspase 3 activity of SAOS cells cultured in suspension was significantly higher ($P \leq 0.0017$) compared to cells allowed to attach to the culture well (Fig. 5,





Fig. 4. SAOS cells undergo apoptosis when adherence is denied. SAOS cells were allowed to adhere to plastic or remain suspended in poly-HEMA coated cell culture wells for 24 h. After culture, cells were fixed and stained with PI. DNA content was analyzed by flow cytometry.

A



B




Fig. 5. Death of SAOS in the absence of adhesion involves cytochrome c release and activation of caspase 3. **A:** Cytochrome c release from mitochondria was detected by immunoblotting 24 h after culture on plastic (lane 1) or on poly-HEMA coated cell culture wells (lane 2). **B:** Caspase 3 activity was determined using a specific fluorogenic substrate after a 24-h incubation on plastic (lane 1) or on poly-HEMA coated wells (lane 2). Results represent the average relative fluorescence (blank fluorescence minus sample fluorescence) of three independent experiments ($P = 0.0017$).

panel B). These results indicate that anoikis of SAOS involves the release of cytochrome c from mitochondria and the activation of the caspase cascade.

Anti- $\alpha 4$ mAb 90B8 Increases Anoikis of Suspended SAOS Cells

The relationship of the integrin $\alpha 4\beta 1$ to SAOS anoikis was determined by incubating specific mAbs with cells for 24 h in adherent and suspended conditions. When SAOS cells are suspended with a mAb specific to the integrin $\alpha 4$ subunit (90B8), a 52% increase in anoikis was found. Other mAbs such as the non-binding IgG control mAb T40/25 or mAbs specific for MHC Class I (W6/32) and $\beta 1$ integrin (33B6 and 87B9) did not increase the level of apoptosis (Fig. 6). In a dose response experiment with the anti- $\alpha 4$

mAb 90B8, increased apoptosis was demonstrated as low as 1.0 picogram (data not shown). The induction of apoptosis after treatment with mAb 90B8 can be observed as early as 6 h with maximum enhancement between 18 and 24 h after treatment (data not shown). Finally, this mAb did not induce apoptosis in adherent SAOS cells indicating that it was not a general cytotoxin (data not shown).

Since anoikis of SAOS involved the release of cytochrome c from mitochondria and the activation of the caspase cascade, we wanted to determine if the increased anoikis observed after treatment with mAb 90B8 correlated with an increase in cytochrome c release and caspase 3 activity. Figure 7 shows a modest increase in the levels of cytochrome c (panel A) and caspase 3 activity (panel B) from suspended SAOS after incubation in the presence of mAb 90B8 in comparison with no antibody treatment or the control mAb W6/32.

DISCUSSION

In this study, we showed the induction of anoikis in SAOS cells after adhesion was denied on poly-HEMA treated cell culture wells. To our knowledge, these results are the first demonstration of anoikis in osteosarcoma cells. Based on the analyses of cell cycle and the results with caspase 3 and cytochrome c, it is fairly certain that the cell death seen in these studies is due




Fig. 6. Treatment of SAOS cells with anti- $\alpha 4$ mAb 90B8 increases anoikis of suspended cells. Suspended (poly-HEMA) SAOS cells were treated with the anti- $\alpha 4$ mAb 90B8, the anti- $\beta 1$ mAbs 33B6 and 87B9, the anti-TCR mAb T40/25, or the anti-human MHC class I mAb W6/32 mAb for 24 h. Percent apoptosis was determined by flow cytometry analysis of DNA content after PI staining. Percentage increase in apoptosis was calculated as follows: (% apoptotic mAb-treated cells – % apoptotic untreated cells) / % apoptotic untreated cells \times 100. Data shown are representative of three independent experiments.




Fig. 7. Cytochrome c release and caspase 3 activity of suspended SAOS after treatment with anti- $\alpha 4$ mAb 90B8. SAOS cells suspended in poly-HEMA coated cell culture wells in the presence of anti- $\alpha 4$ mAb 90B8, anti-human class I mAb W6/32, or medium alone were assayed at 24 h for cytochrome c release (A) and caspase 3 activity (B).

to apoptosis and not necrosis. Under normal conditions cytochrome c resides in the space between the outer and inner membranes of mitochondria. During apoptosis cytochrome c translocates to the cytosol where it controls the assembly of an “apoptosome” composed of Apaf-1 and procaspase-9 [Li et al., 1997; Zou et al., 1999]. The formation of this complex results in the activation of the caspase cascade, which in turn orchestrates the events associated with apoptosis [Hengartner, 2000].

In the analysis of integrin expression on SAOS cells, while there was low expression of $\alpha 3\beta 1$, $\alpha 5\beta 1$, and $\alpha 6\beta 1$, the major $\beta 1$ integrins expressed were $\alpha 1\beta 1$ and $\alpha 4\beta 1$. Recently, others have also shown that the integrin $\alpha 4\beta 1$ is expressed on SAOS [Decker et al., 2002]. The integrin $\alpha 4\beta 1$ was in primary osteosarcoma and metastatic osteosarcoma lesions of lung and pericardium. The expression of $\alpha 4$ integrins is in agreement with a previous report that identified $\alpha 4$ integrin in primary as well as metastatic pulmonary lesion using immunohistochemistry. In that study $\alpha 4$ integrin expression correlated well with the concomitant expression of its ligand, fibronectin, however, the other ligand for the alpha 4 integrin, VCAM-1, was not detected in their specimens [Kawaguchi and

Uede, 1993]. Interestingly, increased levels of α 4 integrin have been found on metastatic sarcoma cells compared to primary sarcomas [Paavonen et al., 1994]. In contrast, expression of α 4 β 1 heterodimers on the melanoma cell line B16 causes decreased matrigel invasion and suppressed pulmonary metastasis formation [Qian et al., 1994].

These observations led us to further examine the role of α 4 integrin during anoikis of osteosarcoma cells. Our findings showed that culture of SAOS cells on poly-HEMA treated cell culture wells induces anoikis. Anoikis was further increased after the addition of the anti- α 4 mAb 90B8. This result was somewhat surprising as it was predicted that antibody binding might send a survival signal that rescues the cells from anoikis. A previous study conducted in our laboratory has shown that the addition of anti-integrin mAbs rescues gastric adenocarcinoma cells from apoptosis despite suspended conditions [Caruso and McIntyre, 2001]. Other studies have shown that soluble collagen and fibronectin can also rescue cells from anoikis [Halvorson et al., 1998; Meerschaert et al., 1999]. In these cases mere ligation of integrins was enough to send the survival signal. In contrast, an integrin knockout model recently developed has shown that lack of α v integrins promotes cell survival and proliferation of endothelial cells resulting in enhanced angiogenesis. They also reported that the lack of integrin interaction, due to the absence of the ligand or by addition of an antagonist, causes cell death. The mechanism was associated with recruitment of caspase-8 to the plasma membrane by unligated integrins [Stupack et al., 2001; Cheresh and Stupack, 2002]. Finally, other investigators have shown that overexpression of integrins, such as α 5 β 1, in intestinal epithelial cells is associated with reduced cell growth that results in protection against apoptosis [Lee and Juliano, 2000].

Our results differ from models whereby integrin ligation saves cells or lack of interaction induces cell death. We show an enhancement of cell death after integrin ligation with the anti- α 4 mAb 90B8. We have not seen this augmentation with soluble ligands of the integrin α 4 β 1 such as VCAM-1 (10 μ g/ml) or the CS-1 region of fibronectin (10 μ g/ml) (data not shown). The fact that the anti- α 4 mAb 90B8 was able to further increase anoikis of SAOS cells suggest that a region of the α 4 integrin

subunit can be involved in the control of cell death. In support of this concept, it was reported that an anti- α 4 antibody induces apoptosis in murine thymocytes [Tchilian et al., 1997]. In our study, anti- β 1 integrin mAbs did not induce anoikis, suggesting that the α 4 subunit could have a unique role in controlling cell death or that the binding of the anti- β 1 mAb to α 1 β 1 can overcome any apoptotic effect of the anti- β 1 mAb binding to α 4 β 1. Because the α 4 and β 1 subunits contain different regions associated with a variety of functions such as induction of adhesion or proliferation [Bednarczyk and McIntyre, 1990; Pulido et al., 1991; Bednarczyk et al., 1993, 1994; Teague and McIntyre, 1994], it is possible that unique sites on the α 4 subunit may regulate anoikis. In support of this concept, we have also seen augmentation of anoikis with another anti- α 4 mAb 91E12 but not with the anti- α 4 mAb L25 or with a mAb 19H8 specific for a combinatorial α 4 β 1 epitope (data not shown).

Induction of anoikis in suspended SAOS after treatment with the anti- α 4 mAb 90B8 correlated with only a modest increase in cytochrome c release and caspase 3 activity. In Figure 5, when adherent cells were placed in suspension for 24 h, an 80% increase in caspase 3 activity was found. In Figure 7 when the anti- α 4 mAb was added there was a 22% increase in caspase 3 activity over the no antibody control. It is not clear if this 22% difference accounts for all of the 52% increase in anoikis found under the same conditions. If not, other mechanisms may be involved, perhaps the activation of integrin-specific mediators such as FAK and subsequently Akt.

Our findings using osteosarcoma cells warrant additional studies to investigate the mechanisms of integrin activation of anoikis and the role of integrins in the pathogenesis of tumor metastasis. These studies may lead to the design of novel antibody and/or inhibitory peptide-based pharmacological approaches for the treatment of osteosarcoma.

REFERENCES

- Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens—new tools for genetic analysis. *Cell* 14:9–20.
- Bednarczyk JL, McIntyre BW. 1990. A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation. *J Immunol* 144:777–784.

- Bednarczyk JL, Carroll SM, Marin C, McIntyre BW. 1991. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. *J Cell Biochem* 46:206–218.
- Bednarczyk JL, Teague TK, Wygant JN, Davis LS, Lipsky PE, McIntyre BW. 1992. Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. *J Leukoc Biol* 52:456–462.
- Bednarczyk JL, Wygant JN, Szabo MC, Molinari-Storey L, Renz M, Fong S, McIntyre BW. 1993. Homotypic leukocyte aggregation triggered by a monoclonal antibody specific for a novel epitope expressed by the integrin beta 1 subunit: Conversion of nonresponsive cells by transfecting human integrin alpha 4 subunit cDNA. *J Cell Biochem* 51:465–478.
- Bednarczyk JL, Szabo MC, Wygant JN, Lazarovits AI, McIntyre BW. 1994. Identification of a combinatorial epitope expressed by the integrin alpha 4 beta 1 heterodimer involved in the regulation of cell adhesion. *J Biol Chem* 269:8348–8354.
- Caruso DA, McIntyre BW. 2001. In an adhesion dependent human gastric adenocarcinoma cell line, integrin ligation without adhesion rescues from anoikis but is not sufficient for cell cycle progression. *Cell Death Differ* 8:665–678.
- Cheresh DA, Stupack DG. 2002. Integrin-mediated death: An explanation of the integrin-knockout phenotype? *Nat Med* 8:193–194.
- Decker S, van Valen F, Vischer P. 2002. Adhesion of osteosarcoma cells to the 70-kDa core region of thrombospondin-1 is mediated by the alpha 4 beta 1 integrin. *Biochem Biophys Res Commun* 293:86–92.
- Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. 1994. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. *J Immunol* 153:517–528.
- Falcioni R, Sacchi A, Resau J, Kennel SJ. 1988. Monoclonal antibody to human carcinoma-associated protein complex: Quantitation in normal and tumor tissue. *Cancer Res* 48:816–821.
- Ferguson WS, Goorin AM. 2001. Current treatment of osteosarcoma. *Cancer Invest* 19:292–315.
- Fogh J, Fogh JM, Orfeo T. 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. *J Natl Cancer Inst* 59:221–226.
- Frisch SM, Francis H. 1994. Disruption of epithelial cell-matrix interactions induces apoptosis. *J Cell Biol* 124:619–626.
- Frisch SM, Screaton RA. 2001. Anoikis mechanisms. *Curr Opin Cell Biol* 13:555–562.
- Goorin AM, Shuster JJ, Baker A, Horowitz ME, Meyer WH, Link MP. 1991. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: Results from the multiinstitutional osteosarcoma study. *J Clin Oncol* 9:600–605.
- Halvorson MJ, Magner W, Coligan JE. 1998. Alpha4 and alpha5 integrins costimulate the CD3-dependent proliferation of fetal thymocytes. *Cell Immunol* 189:1–9.
- Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM, Burakoff SJ, Bhan AK, Springer TA, Strominger JL. 1984. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: Cell distribution and antigenic relation to components on resting cells and T cell lines. *J Immunol* 132:3011–3018.
- Hemler ME, Huang C, Takada Y, Schwarz L, Strominger JL, Clabby ML. 1987. Characterization of the cell surface heterodimer VLA-4 and related peptides. *J Biol Chem* 262:11478–11485.
- Hengartner MO. 2000. The biochemistry of apoptosis. *Nature* 407:770–776.
- Holzmann B, Gossler U, Bittner M. 1998. Alpha 4 integrins and tumor metastasis. *Curr Top Microbiol Immunol* 231:125–141.
- Jia SF, Worth LL, Kleinerman ES. 1999. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. *Clin Exp Metastasis* 17:501–506.
- Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. 1983. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: Identification of constant and variable peptides. *Cell* 35:295–302.
- Kawaguchi S, Uede T. 1993. Distribution of integrins and their matrix ligands in osteogenic sarcomas. *J Orthop Res* 11:386–395.
- Keski-Oja J, Mosher DF, Vaheri A. 1977. Dimeric character of fibronectin, a major cell surface-associated glycoprotein. *Biochem Biophys Res Commun* 74:699–706.
- Lee JW, Juliano RL. 2000. Alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. *Mol Biol Cell* 11:1973–1987.
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91:479–489.
- Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, et al. 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 314:1600–1606.
- McIntyre BW, Evans EL, Bednarczyk JL. 1989. Lymphocyte surface antigen L25 is a member of the integrin receptor superfamily. *J Biol Chem* 264:13745–13750.
- Meerschaert J, Vrtis RF, Shikama Y, Sedgwick JB, Busse WW, Mosher DF. 1999. Engagement of alpha4beta7 integrins by monoclonal antibodies or ligands enhances survival of human eosinophils in vitro. *J Immunol* 163:6217–6227.
- Meredith JE, Jr., Fazeli B, Schwartz MA. 1993. The extracellular matrix as a cell survival factor. *Mol Biol Cell* 4:953–961.
- Meredith JE, Jr., Winitz S, Lewis JM, Hess S, Ren XD, Renshaw MW, Schwartz MA. 1996. The regulation of growth and intracellular signaling by integrins. *Endocr Rev* 17:207–220.
- Paavonen T, Tiisala S, Majuri ML, Bohling T, Renkonen R. 1994. In vivo evidence of the role of alpha 4 beta 1-VCAM-1 interaction in sarcoma, but not in carcinoma extravasation. *Int J Cancer* 58:298–302.
- Pulido R, Elices MJ, Campanero MR, Osborn L, Schiffer S, Garcia-Pardo A, Lobb R, Hemler ME, Sanchez-Madrid F. 1991. Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes. *J Biol Chem* 266:10241–10245.

- Qian F, Vaux DL, Weissman IL. 1994. Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. *Cell* 77:335–347.
- Schwartz MA, Assoian RK. 2001. Integrins and cell proliferation: Regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. *J Cell Sci* 114:2553–2560.
- Schweighoffer T, Tanaka Y, Tidswell M, Erle DJ, Horgan KJ, Luce GE, Lazarovits AI, Buck D, Shaw S. 1993. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4⁺ memory T cells with Hallmarks of gut-trophism. *J Immunol* 151:717–729.
- Shanmugathasan M, Jothy S. 2000. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. *Pathol Int* 50:273–279.
- Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. 1999. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. *Clin Orthop* 358:120–127.
- Sonnenberg A, Janssen H, Hogervorst F, Calafat J, Hilgers J. 1987. A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. *J Biol Chem* 262:10376–10383.
- Streuli CH, Gilmore AP. 1999. Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. *J Mammary Gland Biol Neoplasia* 4:183–191.
- Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresch DA. 2001. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. *J Cell Biol* 155:459–470.
- Tchilian EZ, Owen JJ, Jenkinson EJ. 1997. Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells. *Immunology* 92:321–327.
- Teague TK, McIntyre BW. 1994. MAb 18D3 triggering of integrin beta 1 will prevent but not terminate proliferation of human T cells. *Cell Adhes Commun* 2:169–184.
- Wayner EA, Carter WG, Piotrowicz RS, Kunicki TJ. 1988. The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: Preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa. *J Cell Biol* 107:1881–1891.
- Yawata A, Adachi M, Okuda H, Naishiro Y, Takamura T, Hareyama M, Takayama S, Reed JC, Imai K. 1998. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. *Oncogene* 16:2681–2686.
- Zou H, Li Y, Liu X, Wang X. 1999. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. *J Biol Chem* 274:11549–11546.